TrueBlue, Inc. (NYSE:TBI) Q3 2023 Earnings Call Transcript October 23, 2023 TrueBlue, Inc. beats earnings expectations. Reported EPS is $0.16, expectations were $0.15. Operator: Greetings, and welcome to TrueBlue Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] […]
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis
Vedanta’s pipeline also includes VE303, its Phase 3 ready therapeutic.
PureTech Health subsidiary receives fast track designation for VE202 lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.